Drugs / Sofosbuvir/velpatasvir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02064049 | Oct 2014 → Nov 2019 | hepatitis C virus infection | Kirby Institute | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sofosbuvir/velpatasvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02064049 ↗ |
| Route | Oral | “coformulated into one tablet daily” NCT02064049 ↗ |